This article is for informational purposes only and does not constitute medical advice; consult a qualified healthcare provider before making any health decisions. See our full medical disclaimer.
Key Takeaways
- Fasting glucose and HbA1c can remain in the normal range for years while insulin resistance worsens–a phenomenon called compensatory hyperinsulinemia.
- Fasting insulin and HOMA-IR detect insulin resistance earlier because they measure the body’s compensatory response, not just the downstream glucose signal.
- A triglyceride-to-HDL ratio above 3.0 (using mg/dL values) is a practical, low-cost proxy for insulin resistance available on any standard lipid panel.
- Waist circumference and fasting triglycerides above 150 mg/dL are additional inexpensive clinical signals worth tracking.
- These biomarkers are screening signals, not standalone diagnoses. Elevated values should prompt a clinical conversation, not self-treatment.
The earliest detectable signs of insulin resistance on a blood panel are not fasting glucose or HbA1c–those come late in the process. Fasting insulin, HOMA-IR, and the triglyceride-to-HDL ratio reflect the body’s compensatory strain years before glucose actually rises. If a standard annual physical is the only metabolic screen someone is receiving, there is a meaningful window of early dysfunction that routine testing simply cannot see.
What Is Insulin Resistance, and Why Does Standard Screening Miss It Early?
Insulin resistance is a condition in which cells in the liver, muscle, and fat tissue respond inadequately to insulin, the hormone that signals cells to take up glucose from the bloodstream. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the pancreas responds to this blunted cellular response by producing more insulin to compensate–a state known as compensatory hyperinsulinemia. For a period that can last years or even decades, this compensatory insulin surge keeps blood glucose measurements looking completely normal.
Here is the structural problem with standard screening: both fasting glucose and HbA1c measure the outcome (blood glucose levels), not the underlying cause (declining insulin sensitivity). Fasting glucose is flagged as “impaired” only above 100 mg/dL under ADA 2024 criteria, with prediabetes defined between 100 and 125 mg/dL. A person can have substantial insulin resistance well before reaching 100 mg/dL if the pancreas is compensating robustly enough to hold glucose in check.
The late Stanford physiologist Gerald Reaven described this compensatory mechanism in his landmark 1988 Banting Lecture, naming the cluster of metabolic abnormalities Syndrome X–now widely called metabolic syndrome. His core observation still holds: elevated insulin, not elevated glucose, is the earliest measurable signal. The clinical world has been slow to operationalize that insight in routine screening, which is why a patient can leave an annual physical with reassuring glucose numbers while an undetected metabolic process has been building for years.
The Biomarkers That Detect Insulin Resistance Earlier
None of the following biomarkers are standalone diagnostic tests for insulin resistance. The gold-standard method–the hyperinsulinemic-euglycemic clamp–is a research procedure not used in routine clinical practice. What these markers offer is earlier signal than glucose alone. Think of them as a cluster: the more that are elevated in combination, the stronger the case for a full clinical conversation about metabolic health.
Fasting Insulin
Fasting insulin is the most direct clinically available marker of compensatory hyperinsulinemia. It requires a standard blood draw after an overnight fast of at least 8 hours. Most commercial laboratory reference ranges mark fasting insulin as abnormal only above 25 uIU/mL, a threshold calibrated to avoid flagging false positives across a general population. Multiple metabolic researchers and clinicians–including those at the Cleveland Clinic–note that optimal fasting insulin in a metabolically healthy adult is generally considered to be below 8 to 10 uIU/mL. Values between 10 and 25 uIU/mL represent a gray zone worth clinical attention, particularly when seen alongside other markers.
The important practical point: fasting insulin is not a standard component of most annual physicals. It has to be specifically ordered. Many patients are never tested despite years of progressive insulin resistance because their fasting glucose and HbA1c appear reassuring. The test itself is inexpensive, but it requires a clinician to think to order it.
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance)
HOMA-IR combines fasting glucose and fasting insulin into a single calculated index using the formula developed by Matthews and colleagues in their 1985 Diabetologia paper: HOMA-IR = (fasting insulin [uIU/mL] x fasting glucose [mmol/L]) / 22.5. In studies comparing HOMA-IR to the euglycemic clamp, the correlation is reasonable at the population level, though precision decreases at the extremes of insulin secretion. For non-diabetic adults, a HOMA-IR above 2.0 to 2.5 is commonly used in the research literature as a threshold for insulin resistance; some studies use a cutoff of 1.9 depending on the population studied.
HOMA-IR does not require a separate blood draw–it is derived from two values that may already be available. The main clinical barrier is that fasting insulin is rarely ordered alongside fasting glucose in routine care. Once both values are in hand, the calculation takes seconds.
Triglyceride-to-HDL Ratio
The triglyceride-to-HDL (TG/HDL) ratio is perhaps the most underused signal already sitting inside a standard lipid panel. A ratio above 3.0 (with both values measured in mg/dL) has been associated with insulin resistance and small, dense LDL particles in multiple studies, including work by McLaughlin and colleagues published in Circulation in 2005. A ratio above 3.5 strengthens the association further. Because the lipid panel is already ordered routinely, this calculation costs nothing additional and requires only arithmetic. For context on how lipid markers like this relate to cardiovascular risk, see the detailed breakdown in our comparison of ApoB vs. LDL cholesterol–a distinction that matters for anyone evaluating cardiometabolic risk comprehensively.
Two caveats worth knowing: the TG/HDL ratio performs better as a proxy in non-Hispanic white populations than in other ethnic groups, a limitation that gets glossed over in a lot of popular health writing. Elevated triglycerides can also reflect high dietary carbohydrate intake in the days before the draw, alcohol use, or secondary causes including hypothyroidism. Always verify fasting status and rule out secondary causes before attributing an elevated ratio to insulin resistance.
Fasting Triglycerides
Fasting triglycerides above 150 mg/dL appear in the metabolic syndrome diagnostic criteria as defined by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III, and they remain one of the five components used by the American Heart Association and NIDDK to define the syndrome. Elevated fasting triglycerides in isolation are a weak signal for insulin resistance. In combination with low HDL and central adiposity, the signal becomes substantially more informative.
Waist Circumference
Waist circumference is not a blood test, but it belongs in any honest discussion of insulin resistance biomarkers because it is the most accessible physical measurement available–and one of the most clinically predictive. The NIDDK reports that excess abdominal fat is strongly associated with insulin resistance. Current US clinical thresholds for metabolic risk are waist circumference above 40 inches (102 cm) in men and above 35 inches (88 cm) in women. These cutoffs were derived primarily from European populations, and research has found that metabolic risk can appear at lower waist measurements in South Asian and East Asian populations. Measuring waist circumference at the level of the navel after a normal exhale takes about 30 seconds and costs nothing.
Why HbA1c and Fasting Glucose Miss Early Insulin Resistance
HbA1c measures the percentage of hemoglobin that has been glycated over approximately the preceding 2 to 3 months, reflecting average blood glucose over that window. It is a powerful tool for monitoring established diabetes and for diagnosing prediabetes (5.7 to 6.4%) and diabetes (6.5% or above) as defined in the ADA 2024 Standards of Care. What it cannot do is detect the period during which insulin resistance is rising but the pancreas is still compensating fully. During that window, average blood glucose–and therefore HbA1c–appears normal.
Fasting glucose has the same structural limitation. It measures one downstream variable. If the upstream compensatory mechanism is still intact, the downstream variable will look fine until the pancreas begins to falter–which typically happens years after the insulin resistance itself began. A useful analogy: judging engine health only by whether the car is moving. A compensating engine can keep a car moving long after damage has started accumulating.
The practical consequence is a patient who presents with a fasting glucose of 88 mg/dL and an HbA1c of 5.3%–both squarely normal–while also having a fasting insulin of 18 uIU/mL, a HOMA-IR above 3.5, a TG/HDL ratio of 4.2, and a waist circumference near threshold. That patient’s metabolic trajectory is meaningfully different from someone with the same glucose and HbA1c numbers but a fasting insulin of 6 uIU/mL. Standard screening cannot distinguish the two.
How to Interpret These Markers Together
No single marker here is diagnostic on its own. The value comes from the cluster. A useful framework: treat these markers the way a cardiologist treats a lipid panel–not as simple pass/fail thresholds but as a directional picture of risk over time. For a broader framework on interpreting metabolic and cardiovascular biomarkers in context, the complete biomarkers guide on this site covers the clinical hierarchy from screening to diagnosis across multiple organ systems.
| Biomarker | Reference Points in Literature | Source |
|---|---|---|
| Fasting insulin | Optimal below 8-10 uIU/mL; elevated concern above 15-25 uIU/mL | Cleveland Clinic; NIDDK |
| HOMA-IR | Insulin resistance commonly suggested at above 2.0-2.5 | Matthews et al., Diabetologia 1985 |
| TG/HDL ratio (mg/dL) | Above 3.0 associated with insulin resistance; above 3.5 stronger signal | McLaughlin et al., Circulation 2005 |
| Fasting triglycerides | Above 150 mg/dL flagged in metabolic syndrome criteria | AHA/NCEP ATP III; NIDDK |
| Waist circumference | Above 40 in (men), above 35 in (women) per US metabolic syndrome criteria | NIDDK; AHA |
A pattern worth recognizing: if fasting insulin is elevated alongside a TG/HDL ratio above 3.0 and waist circumference near or above threshold, the probability that standard glucose-based tests are providing a complete metabolic picture is low. That combination warrants a full clinical assessment, not reassurance based on HbA1c alone.
Important Limitations and Clinical Cautions
Elevated fasting insulin can reflect conditions other than insulin resistance, including renal insufficiency, certain medications, and laboratory variability between assays. Insulin immunoassays are not standardized across laboratories the way creatinine or glucose measurements are, which means a value of 14 uIU/mL from one lab may not be equivalent to 14 uIU/mL from another. HOMA-IR inherits this assay variability because it uses fasting insulin as an input. The Mayo Clinic notes that HOMA-IR is primarily a research tool and is not approved by the FDA as a clinical diagnostic test for insulin resistance.
The TG/HDL ratio works best in fasting specimens; non-fasting triglycerides can be substantially higher and render the ratio misleading. Statin therapy lowers LDL but has limited effect on triglycerides or HDL, meaning a patient on a statin can still have a high TG/HDL ratio even after initiating cardiovascular risk reduction. Secondary causes of hypertriglyceridemia–including hypothyroidism, heavy alcohol use, and certain medications–should be considered before attributing an elevated ratio to insulin resistance alone.
None of these values should be used to self-diagnose or self-treat. Interpreting metabolic biomarkers requires clinical context including family history, body composition, medications, and symptoms. Elevated results warrant a conversation with a physician or endocrinologist, not an immediate dietary or pharmaceutical intervention.
Frequently Asked Questions
Can your fasting glucose be normal and you still have insulin resistance?
Yes. This is one of the most clinically important gaps in routine screening. The pancreas compensates for insulin resistance by secreting more insulin, which keeps blood glucose in the normal range for years–sometimes decades–before glucose dysregulation appears. A normal fasting glucose (under 100 mg/dL) does not rule out insulin resistance. Fasting insulin and HOMA-IR are better early signals.
What is a normal fasting insulin level?
Most clinical laboratories flag fasting insulin as abnormal only above roughly 25 uIU/mL, but many metabolic researchers and clinicians consider optimal fasting insulin to be below 8 to 10 uIU/mL. Values between 10 and 25 uIU/mL may indicate early compensatory hyperinsulinemia even when fasting glucose appears normal. Reference ranges vary by lab; context and trends matter more than a single number.
What triglyceride-to-HDL ratio suggests insulin resistance?
A triglyceride-to-HDL ratio calculated from standard fasting lipid values (both in mg/dL) above 3.0 has been associated with insulin resistance in multiple studies, including research published in Circulation (McLaughlin et al., 2005). A ratio above 3.5 raises the signal further. This ratio is a proxy, not a diagnostic test–it should prompt further evaluation rather than a standalone conclusion.
Is HOMA-IR a reliable test for insulin resistance?
HOMA-IR correlates reasonably well with the gold-standard hyperinsulinemic-euglycemic clamp in population studies. A HOMA-IR above 2.0 to 2.5 is often cited in the research literature as the threshold for insulin resistance in non-diabetic adults. The Mayo Clinic notes it is primarily a research tool rather than an FDA-approved clinical diagnostic. Its accuracy is also affected by the lack of standardization across insulin immunoassays, which means results should be interpreted in full clinical context.
Sources
- American Diabetes Association Standards of Medical Care in Diabetes–2024
- NIH/NIDDK: Insulin Resistance and Prediabetes
- McLaughlin T, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine. 2003;139(10):802-809.
- McLaughlin T, et al. Triglyceride and small, dense LDL clearly indicate insulin resistance in non-obese individuals. Circulation. 2005;111:1768-1775.
- Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
- Cleveland Clinic: Insulin Resistance — Symptoms, Causes, Treatment
- Mayo Clinic: Prediabetes
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
